IP Library Granted Patent US 12,091,506
Granted Patent B2
US 12,091,506 · App. 16/402,305 · Granted Sep 17, 2024

Highly soluble tris-(2, 3-epoxypropyl)-isocyanurate and method for producing same

Inventors: Motohiko Hidaka (Tokyo, JP); Takashi Oda (Funabashi, JP); Nobuyuki Kakiuchi (Funabashi, JP); Hiroki Yamaguchi (Funabashi, JP)
Assignee: NISSAN CHEMICAL CORPORATION
C08G73/0644C07D405/14C08G59/3245C08G59/4215C08G59/688C09D179/04C09J179/04Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,091,506
App. No.
16/402,305
Granted
Sep 17, 2024
Kind
B2
Abstract

There is provided an epoxy composition which has difficulty in precipitating a crystal during storage, is homogeneous and can be stored for a long period; and a cured product of the composition having excellent transparency, heat resistance, and light resistance can be obtained on curing. An α-type tris-(2,3-epoxypropyl)-isocyanurate crystal including β-type tris-(2,3-epoxypropyl)-isocyanurate in the crystal in a ratio of 2% by mass to 15% by mass. A method for producing the α-type tris-(2,3-epoxypropyl)-isocyanurate crystal including step (i) separating β-type tris-(2,3-epoxypropyl)-isocyanurate contained in a tris-(2,3-epoxypropyl)-isocyanurate solution from the solution as a solid to obtain a crystal with an increased content ratio of α-type tris-(2,3-epoxypropyl)-isocyanurate.

Claims (16)

1. A curable composition comprising:

an α-type tris-(2,3-epoxypropyl)-isocyanurate crystal comprising β-type tris-(2,3-epoxypropyl)-isocyanurate in the crystal in a ratio of 2% by mass to 7% by mass, wherein the crystal has a particle diameter of 1 μm to 500 μm; and

a carboxylic acid anhydride in a ratio of 0.5 molar equivalent to 1.5 molar equivalent relative to 1 molar equivalent of the crystal, or

a cationic curable compound in a ratio of 0.2 molar equivalent to 5 molar equivalent relative to 1 molar equivalent of the crystal,

wherein the curable composition has a solid content concentration of 1% by mass to 99% by mass, and

wherein when left to stand for one week at room temperature, the curable composition remains clear with no precipitation of tris-(2,3-epoxypropyl)-isocyanurate from the curable composition.

2. A cured product formed by attaching the curable composition according to claim 1 to a substrate and curing the curable composition by heating or light irradiation.

3. The cured product according to claim 2 , wherein the attaching to the substrate is carried out by application, filling, adhesion, or impregnation.

4. The curable composition according to claim 1 , wherein the curable composition is liquid, transparent and homogeneous.

5. The curable composition according to claim 1 , wherein the carboxylic acid anhydride is present, and wherein the carboxylic acid anhydride is liquid at room temperature and is selected from the group consisting of 3-methyl-cyclohexane dicarboxylic acid anhydride, 4-methyl-cyclohexane dicarboxylic acid anhydride, and a mixture of 3-methyl-cyclohexane dicarboxylic acid anhydride and 4-methyl-cyclohexane dicarboxylic acid anhydride.

6. A method for producing a curable composition comprising

mixing an α-type tris-(2,3-epoxypropyl)-isocyanurate crystal comprising β-type tris-(2,3-epoxypropyl)-isocyanurate in the crystal in a ratio of 2% by mass to 7% by mass and the crystal having a particle diameter of 1 μm to 500 μm, and

a carboxylic acid anhydride in a ratio of 0.5 molar equivalent to 1.5 molar equivalent relative to 1 molar equivalent of the crystal, or

a cationic curable compound in a ratio of 0.2 molar equivalent to 5 molar equivalent relative to 1 molar equivalent of the crystal,

wherein the curable composition has a solid content concentration of 1% by mass to 99% by mass, and

wherein when left to stand for one week at room temperature, the curable composition remains clear with no precipitation of tris-(2,3-epoxypropyl)-isocyanurate from the curable composition.

Assignments (1)
CHANGE OF NAME Recorded Jul 10, 2019
From: NISSAN CHEMICAL CORPORATION
To: NISSAN CHEMICAL CORPORATION
Reel/Frame 049720/0786 →
Priority Claims (1)
JP 2013-003377 · Jan 11, 2013 · national
Continuity (2)
Division 14759486
Related Publication 20190256657A1 · Aug 22, 2019